(B)
| Patients | Age at diagnosis (years) | Gender | Backbone treatment | Other treatment | OS (months) |
|---|---|---|---|---|---|
| 10 | 4.06 | F | RTX + N/V | No (refused) | 7.10 |
| 11 | 5.44 | M | RTX + N/V | Bevacizumab temozolomide re-irradiation |
14.33 |
| 12 | 6.10 | M | RTX + N/V | Bevacizumab temozolomide |
24.47 |
| 13 | 4.18 | F | RTX + N/V | Bevacizumab temozolomide re-irradiation |
21.97 |
| 14 | 5.56 | M | RTX + N/V | Bevacizumab temozolomide re-irradiation |
11.40 |
| 15 | 9.44 | F | RTX + temozolomide | Bevacizumab N/V re-irradiation |
18.53 |
| 16 | 6.62 | F | RTX + N/V | Bevacizumab temozolomide |
13.33 |
| 17 | 9.31 | F | RTX + N/V | Bevacizumab temozolomide re-irradiation |
14.17 |
| 18 | 3.60 | F | RTX + N/V | Bevacizumab temozolomide re-irradiation |
15.03 |
| 19 | 6.05 | M | RTX + N/V | No (refused) | 7.43 |
| 20 | 6.66 | F | RTX + N/V | Bevacizumab temozolomide re-irradiation |
21.87 |
| 21 | 5.58 | F | RTX + N/V | No (refused) | 4.90 |
| 22 | 5.04 | F | RTX + N/V | Bevacizumab temozolomide re-irradiation |
17.57 |
| 23 | 7.73 | M | RTX + N/V | Bevacizumab temozolomide re-irradiation |
12.27 |
| 24 | 14.71 | M | RTX + N/V | Bevacizumab temozolomide |
7.87 |
| 25 | 6.35 | F | RTX + N/V | Bevacizumab temozolomide re-irradiation |
13.77 |
N, nimotuzumab; OS, overall survival; RTX, radiotherapy; V, vinorelbine.